The FDA plans to issue a new rule declaring drug labels approved by the agency pre-empt state regulations, a development that could help drug firms defend against liability lawsuits. The policy is expected to be issued as part of a larger drug-labeling rule intended to make drug information more accessible by using a new format.

Related Summaries